Krystal Biotech
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 days.
- Its last 6 Sell calls were actually followed by a +15% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +21.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 10.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 42.0x | Better than 12% |
| Forward P/E | 32.4x | Better than 16% |
| Price / Sales | 19.2x | Better than 6% |
| P/E vs own 5-yr range | 68th pctl | Better than 40% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 94.1% | Better than 98% |
| Operating margin | 41.5% | Better than 96% |
| Net margin | 52.6% | Better than 97% |
| Return on equity | 18.9% | Better than 76% |
| Return on invested capital | 16.8% | Better than 85% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -10.9% | Better than 49% |
| 6-month return | 3.2% | Better than 62% |
| 12-month return (ex latest month) | 46.9% | Better than 82% |
| Distance below 52-week high | 19.3% | Better than 62% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 10.0x | Better than 93% |
| Debt to assets | 0.7% | Better than 95% |
| Interest coverage | -45.6x | Better than 7% |
| Free cash flow / net income | 92.2% | Better than 33% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 27.3% | Better than 44% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 315.82
- Open
- 313.38
- Day range
- 308.22 - 321.27
- Avg price
- 312.40
- Volume
- 286.70K
- Turnover
- 89.57M
- Turnover ratei
- 1.21%
- Volume ratioi
- 1.28
- Amplitudei
- 4.13%
- 52-week rangei
- 212.02 - 382.54
Valuation
- P/Ei
- 45.16
- P/E (TTM)i
- 41.97
- P/Bi
- 6.38
- EPSi
- 6.84
- Book value / shi
- 48.45
- Net profit
- 202.69M
- Net assets
- 1.44B
Share structure
- Market cap
- 9.15B
- Float capi
- 7.31B
- Shares out
- 29.63M
- Float sharesi
- 23.66M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2017-09-20
19.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-15.04M net over the window
Short interest
- Shares short
- 3.04M
- % of floati
- 10.29%
- Days to coveri
- 12.23
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Krystal Biotech (KRYS)?
Krystal Biotech last traded at 308.89. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Krystal Biotech's market cap?
About 9.15B.
What is the P/E ratio of Krystal Biotech?
The trailing twelve-month P/E is 41.97, above its own 5-year average of 29.75 — toward the top of its historical range (68.34% percentile). See the Valuation tab for the full history.
Does Krystal Biotech pay a dividend?
Krystal Biotech does not currently pay a regular dividend.
Is Krystal Biotech a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 393.17, which implies 27.3% upside from the current price. This is not investment advice.
What is Krystal Biotech's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Krystal Biotech a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Krystal Biotech discussion 0 comments